A peptide vaccine derived from LY6K (LY6K-177) exhibited favorable immunogenicity in a Phase I clinical trial, inducing CD8+ T cell-specific cytotoxicity against LY6K-expressing ESCC cells (Ishikawa et al., 2014). This evidence concerns the gene LY6K and esophageal squamous cell carcinoma.